This 2021 study conducted a multi-country economic analysis to assess the financial impact of cardiovascular and metabolic adverse events, including weight gain, associated with second-generation antipsychotics (SGAs) in the treatment of schizophrenia. The research highlighted that SGAs, while effective in managing schizophrenia symptoms, are linked to significant metabolic side effects
